Thiogenesis Therapeutics Corp.
Symbol:
TSXV: TTI
OTCPK: TTIPF
Market Cap:
36M
Purpose
Raise Awareness, Open Market Buying
Sector:
Biotechnology
Summary:
- Developing prodrugs that act as precursors to thiol-active compounds – with the potential to treat serious pediatric diseases.
- Thiols have powerful antioxidant properties that may address oxidative stress in the mitochondria (“powerhouse of the cell”) – mitochondrial dysfunction and oxidative stress are at the core of many metabolic disorders.
- In 2024, planning to initiate Phase 2 clinical trials in a mitochondrial disease, Rett syndrome and pediatric NASH.